First patient enrolled in BrainStorm ALS Phase 2

|About: BrainStorm Cell Therap... (BCLI)|By:, SA News Editor

The first patient has been enrolled in BrainStorm Cell Therapeutics' (BCLI) Phase 2 ALS clinical trial at Mass General Hospital in Boston. The study will evaluate the safety and efficacy of the transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors ("MSC-NTF" or "NurOwn") in 48 ALS patients at three hospitals (Mass General, UMass Hospital in Worcester and the Mayo Clinic in Rochester, NY).

NurOwn is an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into MSC-NTF cells. These neuron-supporting cells secrete elevated levels of neurotrophic factors that protect existing motor neurons, promote motor neuron growth and re-establish nerve-muscle interaction.